{
    "nctId": "NCT06268327",
    "briefTitle": "Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy",
    "officialTitle": "Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Adding adjuvant cisplatin and gemcitabine versus capecitabine in triple-negative Breast cancer patients with non pathologically complete response after neoadjuvant standard chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age: 20 years and older.\n* Patients with no clinical/radiologic distant metastasis.\n* Tumor type: Invasive ductal carcinoma or invaive lobular carcinoma.\n* Tumor subtype: triple negative\n* patients had operable, primary invasive, noninflammatory early stage I-IIIB TNBC (ER and PR \\<1%, HER2 score: 0 or 1)\n* Patients with a good performance status (0/1)\n* Patients with adequate hematological, cardiac, renal, and hepatic function\n\nExclusion Criteria:\n\n* Patients who achieve pathologic complete response after neoadjuvant chemotherapy\n* inflammatory breast cancer\n* Breast cancer patients with distant metastasis\n* Patient with hormonal receptor positive /HER2 +ve",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}